Bafna Pharmaceuticals Limited Overview
Bafna Pharmaceuticals is a micro-cap, export-oriented Indian manufacturer of finished oral solid-dose formulations operating from a single Chennai plant at Grantlyon that holds UK-MHRA, EU-GMP, TGA (Australia), WHO-GMP and revised Schedule-M accreditations. The company runs two linked business models: contract manufacturing (CRAMS) for regulated-market marketing-authorisation holders in the UK, Europe and Australia, and sale of its own generics and branded generics into semi-regulated markets in Africa, Asia, CIS and Latin America. Its 336-formulation portfolio leans towards chronic "lifestyle" therapies — diabetes, CNS, cardiovascular and potent oncology/hormonal products — which made up about two-thirds of FY2025 revenue. The company emerged in 2020 from an NCLT-approved resolution process, after which SRJR Lifesciences LLP became promoter. FY2026 revenue was INR 1,506 M with EBITDA of INR 207 M. The stock has re-rated sharply, to above 140x trailing earnings, despite a weak Q1 FY2027.
The company's own description (Annual Report FY2025-26)
The FY2025-26 Annual Report describes Bafna as a 31-year-old listed pharmaceutical company engaged in the development, manufacture and global export of finished formulations. It says the company began as an institutional supplier, became a generic player, and is now a contract research and manufacturing services (CRAMS) partner. It exports branded generics and formulations to more than 20 countries across regulated and emerging markets. The report states that 100% of production, including deemed exports, goes to healthcare markets in Asia, Australia, West and East Africa, Europe, the UK and Latin America. The portfolio is stated at 336 product formulations covering antibiotics, anti-infectives, nutritional supplements, cardiovascular, diabetes, CNS and potent oncology therapies.
The report's stated vision is to become a global pharmaceutical company recognised for specialty generics, moving up the value chain under the banner "Wellness Beyond Boundaries". Its mission is to supply affordable, high-quality formulations from its accredited facility while maintaining cost leadership and regulatory standards.
Independent characterisation
In economic terms, Bafna is a sub-scale, capacity-led solid-oral contract manufacturer and dossier-led generic exporter. ICRA (Jan 2026) describes the model in two parts: contract manufacturing for regulated markets and sale of generics in semi-regulated or unregulated markets.
Revenue model: Nearly all revenue is product sales of manufactured finished dosage forms. There is no material subscription or licensing income. The "Out-Licensing" pillar of the Bafna 2.0 strategy is aspirational, and no licensing revenue has been disclosed. Other income (INR 47.6 M in FY2026) consists largely of export incentives, foreign-exchange gains and interest, and is non-core.
Value-chain position: Bafna is a downstream formulator. It buys APIs and excipients (part of them imported; FX outgo was INR 91.4 M in FY2026) and converts them into tablets and capsules. It also owns or prepares dossiers for product registrations in export markets. It does not manufacture APIs. Its in-house DSIR-recognised formulation R&D unit develops and scales up formulations and prepares registration dossiers.
Customer types: - Regulated-market marketing-authorisation holders and distributors. Named examples in ICRA rationales are Relonchem Limited (UK), Arrow Pharmaceuticals Pty Ltd (Australia, 2022) and Strides Pharma Science Limited.
-
Indian merchant exporters and pharma companies buying on a deemed-export basis, such as Tenshi Kaizen Private Limited and Cipla Limited (named in 2022).
-
Importers and distributors in emerging markets, for example Nigeria, the Philippines, Sri Lanka, Tanzania, Ethiopia and Ukraine.
Concentration: Customer concentration is extreme. ICRA reports that 78.4% of FY2025 sales came from the top 5 customers (elsewhere stated as "over 75%"). The top 5 products made up 56% of FY2025 revenue, and the top 3 molecules — Metformin, Fluoxetine and Lithium Carbonate — made up 45.0%.
End-markets: Demand comes from chronic-therapy generics in the UK and Australia (largely through NHS and PBS-type procurement via MAH customers) and from out-of-pocket or tender-driven markets in Africa and Asia. ICRA puts the lifestyle-disease share at 67.2% of FY2025 revenue (diabetology, CNS, pain management and others).
How the model makes money
Profitability depends on three factors: capacity utilisation at a single plant, product mix (high-margin "potent" and specialty orders versus commodity molecules such as metformin), and working-capital discipline. ICRA attributes the jump in operating margin to 15.1% in H1 FY2026 to a favourable product mix and some high-margin orders. That margin was not sustained: reported operating margin (excluding other income) fell back to 8.0% in Q3 FY2026 and 8.4% in Q4 FY2026, and Q1 FY2027 PAT almost disappeared. The business therefore behaves like a lumpy order-book manufacturer, not an annuity franchise.
Strategy
Stated strategy — "Bafna 2.0" (AR FY2025-26)
| Pillar | Stated initiatives |
|---|---|
| 1. Geographic expansion & regulatory roadmap | North America entry with diabetes and oncology formulations; scale in the UK, Europe, Australia, MENA, Sri Lanka, Philippines and CIS; file 6–8 new dossiers a year; begin regulatory groundwork in LATAM and CIS |
| 2. Branded generics & strategic partnerships | Scale high-margin branded generics in target regulated markets; alliances with tier-one regional distributors and local manufacturing partners to overcome trade barriers; asset-light out-licensing of proprietary products |
| 3. Global visibility & trade engagement | Participation in CPHI Worldwide and similar events; use compliance and R&D credentials to win co-marketing and supply agreements |
| 4. Digital reach & commercial digitalisation | Digital B2B campaigns and virtual meetings; digital systems to track distributor pipelines and dossier requests |
The Annual Report presents Bafna 2.0 as moving the company from a traditional manufacturer to an agile, globally recognised pharmaceutical company. It rests on three moves — shifting to high-value therapies, using strategic alliances and modernising commercial operations — organised in four pillars:
Initiatives executed in the last 24 months
| Initiative | Timing | Detail / status |
|---|---|---|
| Capsule capacity expansion | FY2026 | 375 M to 600 M units; utilisation about 30% |
| Dedicated granulation facility | FY2026 | Commissioned (CEO letter) |
| QC/QA laboratory upgrade | FY2026 | Modern analytical instrumentation |
| High-containment potent-drug zones | FY2025–FY2026 | Expanded potent oncology and hormonal capability |
| Madhavaram unit divestment | Board approval Aug 2024; completed Jun 2025 | INR 14.51 M sale; consolidation at Grantlyon |
| Solar PPA | FY2026 | About 60% of plant power from solar |
| Regulatory filings | FY2026 | 51 new registrations; about 100 pending |
| MHRA re-inspection | FY2026 | "Satisfactorily completed" |
| Minimum public shareholding compliance | Mar–Apr 2025 | 13.30% promoter OFS |
| Sachet dosage line | Pipeline | Not dated |
Medium-term targets and guidance
EBITDA margin of at least 15%: (AR FY2026 financial highlights). FY2026 achieved 13.75%; Q1 FY2027 was well below this.
6–8 new dossier filings a year: - "Minimum-debt status" with prudent capex and working-capital control (AR FY2026). This sits uneasily with the rise in total debt to INR 374 M in FY2026.
Capex: of INR 200 M for FY2026 and INR 75 M for FY2027, funded from accruals and debt (ICRA, Jan 2026).
- No numerical revenue guidance has been given publicly. The company holds no earnings calls and no investor-day transcripts exist.
ESG commitments
The company has a solar sourcing target of up to 60% of plant power (reported as achieved), water recycling and rainwater harvesting, a TNPCB-certified ETP, and CSR spending of INR 1.805 M in FY2026, which met the 2% obligation in full.
Products & Services
The company does not disclose product-level revenue, SKU-level pricing or launch dates. The catalog below is built from the FY2025-26 Annual Report's "Core Therapeutic Offerings" table and from ICRA product disclosures. Pricing is not publicly disclosed for any product. Revenue is earned on per-unit B2B supply prices or contract-manufacturing conversion fees.
Cardiovascular & hypertension (tablets)
| Molecule | Description / use | Target markets (AR FY2026) |
|---|---|---|
| Telmisartan | Angiotensin-II receptor blocker (ARB) for hypertension | Asia, Africa, Central/South America, Australia, UK |
| Losartan | ARB for hypertension and diabetic nephropathy | Same |
| Olmesartan | ARB for hypertension | Same |
| Atorvastatin | Statin for dyslipidaemia | Same |
| Simvastatin | Statin | Same |
| Clopidogrel | Antiplatelet agent | Same |
| Lisinopril | ACE inhibitor | Same |
| Atenolol (listed as "Atenolyl") | Beta-blocker | Same |
| Propranolol | Non-selective beta-blocker | Same |
| Amlodipine | Calcium-channel blocker | Same |
Diabetes (tablets)
| Molecule | Description | Target markets |
|---|---|---|
| Metformin | Biguanide; first-line type-2 diabetes therapy. One of the top 3 revenue molecules in FY2025 | Asia, Africa, Australia, UK |
| Sitagliptin | DPP-4 inhibitor | Same |
| Vildagliptin | DPP-4 inhibitor | Same |
| Dapagliflozin | SGLT2 inhibitor | Same |
| Empagliflozin | SGLT2 inhibitor | Same |
| Glimepiride | Sulfonylurea | Same |
The Bafna 2.0 strategy names advanced diabetes formulations as a candidate for North American entry. No US or Canadian filing has been disclosed.
Central nervous system (tablets, capsules)
| Molecule | Description | Target markets |
|---|---|---|
| Fluoxetine | SSRI antidepressant (capsules or tablets). One of the top 3 revenue molecules in FY2025 | UK, Asia, Africa, Central/South America |
| Lithium Carbonate | Mood stabiliser for bipolar disorder. One of the top 3 revenue molecules in FY2025 | Same (named by ICRA) |
| Pregabalin | Neuropathic pain / anticonvulsant (capsules) | Same |
| Gabapentin | Anticonvulsant / neuropathic pain | Same |
| Levetiracetam | Anti-epileptic | Same |
| Clonazepam | Benzodiazepine anticonvulsant / anxiolytic | Same |
Potent oncology & hormonal (tablets; high-containment manufacturing)
| Molecule | Description | Target markets |
|---|---|---|
| Prednisolone (incl. enteric-coated) | Corticosteroid. The company says it was the first to launch generic Prednisolone EC tablets in the UK (launch year not disclosed) | UK, Asia, Africa, Central/South America |
| Tamoxifen | Selective oestrogen receptor modulator (breast cancer) | Same |
| Letrozole | Aromatase inhibitor (breast cancer) | Same |
| Bicalutamide | Anti-androgen (prostate cancer) | Same |
| Finasteride | 5-alpha-reductase inhibitor (BPH / alopecia) | Same |
The FY2026 CEO letter states that capabilities in potent drug products were expanded during the year, supported by dedicated high-containment zones.
Anti-infectives (tablets)
| Molecule | Description | Target markets |
|---|---|---|
| Levofloxacin | Fluoroquinolone antibiotic | Asia, Africa, Central/South America |
| Moxifloxacin | Fluoroquinolone antibiotic | Same |
| Azithromycin | Macrolide antibiotic | Same |
| Linezolid | Oxazolidinone antibiotic | Same |
The company's heritage includes beta-lactam and non-beta-lactam products. Whether beta-lactam manufacturing continues at Grantlyon after the Madhavaram divestment is not publicly disclosed.
Nutritional supplements and other
The FY2026 Annual Report lists nutritional supplements among its therapy areas without naming products. Raricap (an oral haematinic, acquired from J&J in 2011) was sold to Strides in 2014. Strides acquired global rights to the brand, while Bafna reportedly retained some global (ex-India) rights at the time.
Services: CRAMS and specialty
| Offering | Description | Customers / markets |
|---|---|---|
| Contract manufacturing | Custom solid-oral manufacture for MAH partners | UK, Australia, EU partners |
| Contract research / dossier filings | Formulation development and preparation of CTD dossiers for partners | Same |
| Specialty technologies (FR&D) | Bi-layer tablets, modified-release solids, gastro-resistant and multi-layer coatings, ion-exchange-resin taste masking, stability-challenging molecules, potent/hormonal handling | Platform capabilities; no named products |
| Pipeline: sachet oral dosage | New dosage-form line described as "coming soon" | — |
Registration footprint (AR FY2025-26)
The company reports 336 active formulations, "78+ global product registrations", active registrations in more than 20 countries, and about 100 applications pending. Fifty-one new registrations were obtained in FY2026:
Product Portfolio
| Country | New registrations FY2026 |
|---|---|
Philippines | 20 |
Nigeria | 13 |
Australia | 5 |
Sri Lanka | 4 |
Azerbaijan | 3 |
Ghana | 2 |
Tanzania | 2 |
Bolivia | 1 |
Georgia | 1 |
Total | 51 |
Financial Narrative
Basis.
-
FY2023–FY2026 P&L items come from the Annual Reports (Directors' Report tables and the FY2026 five-year summary).
-
FY2022 items and all balance-sheet and cash-flow lines come from S&P Global Market Intelligence (via StockAnalysis), which is standardised from the filings.
-
Ratios are analyst-computed unless noted.
-
Currency is INR million. EPS for FY2022–FY2024 is computed on 23,656,335 shares; FY2025 and FY2026 EPS are as reported.
Income statement
Revenue CAGR: 15.3% over FY2022–FY2026 (4 years); 9.3% over FY2023–FY2026 (3 years).
Commentary. The five years divide into three phases:
Post-resolution recovery (FY2022–FY2023): Revenue grew 35% to INR 1,154 M and EBITDA margin held at about 16%, as regulated-market CRAMS volumes ramped from a depressed base.
Volume-over-margin (FY2024–FY2025): FY2024 revenue rose a further 32%, but gross margin fell about 370 bp to 29.9% and EBITDA margin collapsed to 9.6%. This points to a shift towards lower-priced commodity chronic molecules (metformin, fluoxetine, lithium) and higher costs. FY2025 revenue then fell 4.3%. ICRA attributes the decline to machinery breakdowns and regulatory audits that disrupted production.
Mix-led margin recovery (FY2026): Revenue grew only 3.3%, but exports rose 31.3% while domestic and deemed-export sales fell about 25%. Gross margin recovered to 32.0% and EBITDA rose 49% to INR 207 M, a 13.75% margin. Management now targets an EBITDA margin of at least 15%.
The FY2026 improvement was front-loaded. ICRA's 15.1% H1 margin compares with reported operating margins (excluding other income) of 7.97% in Q3 and 8.40% in Q4. A rising share of other income (INR 47.6 M, 23% of EBITDA) also flattered the result.
Quarterly trajectory (last nine quarters)
Sources: Capital Market / Business Standard result summaries and company filings. Q1 FY2027 sales are derived from the reported 23.22% year-on-year decline versus Q1 FY2026 sales of INR 34.62 crore. Reported operating margins (excluding other income) were:
-
9.42% in Q2 FY2025, 9.25% in Q3 FY2025 and 7.96% in Q4 FY2025;
-
12.04% in Q2 FY2026, 7.97% in Q3 FY2026 and 8.40% in Q4 FY2026.
Q1 FY2027 is the weakest quarter in the series. Trailing-twelve-month PAT has fallen to about INR 77.9 M (INR 7.79 crore). The cause of the revenue decline (order timing, plant shutdown, customer destocking or audit) has not been explained in any public commentary found.
Balance sheet
Commentary. Capex of INR 155.8 M in FY2024, INR 218.6 M in FY2025 and INR 249.0 M in FY2026 (about 41% of three-year revenue on a cumulative basis) more than doubled net PP&E, from INR 388 M to INR 849 M. The spend went on granulation, capsule capacity (375 M to 600 M units), QC/QA laboratory upgrades and high-containment zones. It was funded mainly by debt: total debt rose 3.4x from FY2022. The near-term debt profile has worsened. The current portion of long-term debt jumped to INR 196.5 M at FY2026 from INR 56.0 M at FY2025, and cash was only INR 20.3 M, so refinancing or accrual-funded repayment in FY2027 is a monitorable. Gearing remains moderate at 0.39x debt to S&P equity, or about 0.54x on the company's net worth basis.
Cash flow
Source: S&P Global via StockAnalysis.
Cumulative five-year free cash flow is negative INR 149 M. The business has not yet self-funded its capacity build. FY2025's strong operating cash flow (INR 221 M) came from a working-capital release: receivables fell by INR 55 M as collections improved, which is consistent with ICRA's note that working-capital intensity fell to 30.9% from above 40%. That release partly reversed in FY2026. ICRA had guided capex of INR 200 M for FY2026 and INR 75 M for FY2027; the actual FY2026 figure (INR 249 M) exceeded guidance. If FY2027 capex normalises to about INR 75 M, positive free cash flow becomes plausible, provided operating cash flow recovers from the weak Q1.
Ratios
Basis. ROE, ROA, ROIC, ROCE, the liquidity ratios, D/E and turnover ratios are from S&P Global. Coverage ratios, net debt/EBITDA and the cash conversion cycle are analyst-computed from year-end balances and S&P cost of revenue. The company-reported return on net worth was 6.86% for FY2025 and 15.31% for FY2026. ICRA-adjusted ratios are: Total debt/OPBDITA of 1.7x (FY2024), 2.1x (FY2025) and 1.6x (H1 FY2026); interest coverage of 6.1x, 5.0x and 6.0x for the same periods.
Commentary. Returns peaked in FY2023 (ROIC 14.2%), troughed in FY2025 (6.5%) and recovered only partly in FY2026 (8.8%). This is close to or below a plausible INR cost of capital for a BB+ rated micro-cap. The cash conversion cycle of 90–100 days is typical for an export CDMO with credit terms to MAH customers. Overdue export receivables of about INR 12.3 M beyond RBI realisation timelines (auditor's emphasis of matter, Q1 FY2026) show some collection risk in semi-regulated markets. Interest coverage has roughly halved since FY2023 as debt-funded capex built up.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Segment (Ind AS 108) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pharmaceutical formulations — revenue (INR Mn) | 1,524.66 | 1,458.57 | 1,506.17 |
YoY growth (%) | 32.18 | -4.33 | 3.26 |
Share of total revenue (%) | 100 | 100 | 100 |
Segment PBT before exceptional (INR Mn) | 73.48 | 62.08 | 109.70 |
Segment PBT margin (%) | 4.82 | 4.26 | 7.28 |
Disclosure Details
| Disclosure | Value | Period | Source |
|---|---|---|---|
Lifestyle-disease therapies, share of revenue | 67.1% | FY2022 | ICRA, Nov 2022 |
Lifestyle-disease therapies, share of revenue | 67.2% | FY2025 | ICRA, Jan 2026 |
Top 3 products (Metformin, Fluoxetine, Lithium Carbonate), share of revenue | 45.0% | FY2025 | ICRA, Jan 2026 |
Top 5 products, share of revenue | 56% | FY2025 | ICRA, Jan 2026 |
Top 5 customers, share of sales | 78.4% | FY2025 | ICRA, Jan 2026 |
Export sales | INR 958.10 M (63.6% of revenue) | FY2026 | AR FY2025-26 |
Export sales | INR 729.78 M (50.0% of revenue) | FY2025 | AR FY2025-26 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 851.40 | 1,153.50 | 1,524.66 | 1,458.57 | 1,506.17 |
Revenue growth (%) | 19.55 | 35.48 | 32.18 | -4.33 | 3.26 |
Other income (INR Mn) | 16.98 | 32.73 | 35.22 | 27.42 | 47.56 |
Total income (INR Mn) | 868.38 | 1,186.22 | 1,559.88 | 1,485.99 | 1,553.73 |
Gross profit (INR Mn) | 338.60 | 387.60 | 455.59 | 427.96 | 481.34 |
Gross margin (%) | 39.77 | 33.60 | 29.88 | 29.34 | 31.96 |
EBITDA incl. other income (INR Mn) | 136.60 | 189.88 | 146.34 | 139.19 | 207.04 |
EBITDA margin on revenue (%) | 16.04 | 16.46 | 9.60 | 9.54 | 13.75 |
Depreciation & amortisation (INR Mn) | 54.93 | 53.34 | 49.95 | 48.90 | 60.73 |
EBIT (INR Mn) | 81.67 | 136.54 | 96.38 | 90.29 | 146.31 |
EBIT margin (%) | 9.59 | 11.84 | 6.32 | 6.19 | 9.71 |
Finance cost (INR Mn) | 5.24 | 20.38 | 22.90 | 27.31 | 36.61 |
PBT before exceptional items (INR Mn) | 73.62 | 116.16 | 73.48 | 62.08 | 109.70 |
Exceptional items (INR Mn) | 0 | 0 | 0 | -21.46 | 0 |
Net profit / PAT (INR Mn) | 52.16 | 113.38 | 73.48 | 41.53 | 111.00 |
Net margin (%) | 6.13 | 9.83 | 4.82 | 2.85 | 7.37 |
EPS basic (INR) | 2.20 | 4.79 | 3.11 | 1.76 | 4.69 |
EPS diluted (INR) | 2.20 | 4.79 | 3.11 | 1.76 | 4.69 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 | 35.47 | 38.29 | 42.24 | 26.58 |
PAT (INR Cr) | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 | 1.84 | 2.75 | 0.08 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 901.45 | 1,296.00 | 1,477.00 | 1,531.00 | 1,755.00 |
Cash & equivalents (INR Mn) | 1.73 | 78.09 | 13.96 | 34.33 | 20.25 |
Trade & other receivables (INR Mn) | 148.76 | 412.03 | 454.77 | 401.97 | 440.07 |
Inventory (INR Mn) | 202.81 | 222.20 | 296.42 | 280.86 | 289.03 |
Property, plant & equipment (INR Mn) | 388.46 | 402.30 | 507.07 | 660.93 | 849.24 |
Goodwill & intangibles (INR Mn) | 0 | 15.00 | 17.70 | 0 | 0 |
Short-term debt incl. current LTD (INR Mn) | 57.43 | 144.90 | 136.36 | 141.70 | 196.51 |
Long-term debt (INR Mn) | 53.17 | 84.33 | 107.53 | 140.29 | 177.82 |
Total debt (INR Mn) | 110.59 | 229.24 | 243.89 | 281.99 | 374.33 |
Net debt (INR Mn) | 108.86 | 151.15 | 229.93 | 247.66 | 354.09 |
Accounts payable (INR Mn) | 124.05 | 284.61 | 354.22 | 309.45 | 312.86 |
Shareholders' equity, S&P basis (INR Mn) | 619.64 | 734.55 | 808.39 | 848.07 | 961.50 |
Net worth, company basis (INR Mn) | 349.80 | 464.70 | 538.60 | 578.30 | 691.60 |
Working capital (INR Mn) | 288.67 | 408.35 | 396.88 | 343.27 | 324.63 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | 97.28 | 49.53 | 94.85 | 221.36 | 153.71 |
Capital expenditure (INR Mn) | 75.41 | 67.19 | 155.78 | 218.60 | 249.03 |
Free cash flow (INR Mn) | 21.87 | -17.66 | -60.93 | 2.76 | -95.32 |
Change in working capital (INR Mn) | -7.95 | -144.20 | -52.80 | 75.49 | -56.05 |
Net debt issued / (repaid) (INR Mn) | -47.27 | 118.65 | 14.65 | 38.09 | 92.35 |
Cash interest paid (INR Mn) | 0.88 | 16.87 | 23.11 | 27.46 | 36.12 |
Dividends paid (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, S&P equity basis (%) | 8.79 | 16.74 | 9.53 | 5.01 | 12.27 |
ROA (%) | 4.70 | 6.70 | 3.31 | 2.89 | 4.02 |
ROIC (%) | 9.25 | 14.24 | 7.63 | 6.51 | 8.76 |
ROCE (%) | 9.70 | 14.20 | 7.80 | 6.90 | 8.90 |
Current ratio (x) | 2.31 | 1.88 | 1.73 | 1.63 | 1.57 |
Quick ratio (x) | 0.68 | 1.05 | 0.87 | 0.84 | 0.80 |
Debt / equity (x) | 0.18 | 0.31 | 0.30 | 0.33 | 0.39 |
Net debt / EBITDA, company EBITDA (x) | 0.80 | 0.80 | 1.57 | 1.78 | 1.71 |
EBITDA / interest (x) | 26.07 | 9.32 | 6.39 | 5.10 | 5.66 |
EBIT / interest (x) | 15.59 | 6.70 | 4.21 | 3.31 | 4.00 |
Asset turnover (x) | 0.96 | 1.05 | 1.10 | 0.97 | 0.92 |
Inventory turnover (x) | 2.89 | 3.62 | 4.14 | 3.58 | 3.61 |
Receivable days (DSO) | 63.8 | 130.4 | 108.9 | 100.6 | 106.6 |
Inventory days (DIO) | 143.6 | 105.3 | 100.8 | 99.1 | 102.9 |
Payable days (DPO) | 87.8 | 134.9 | 120.5 | 109.2 | 111.4 |
Cash conversion cycle (days) | 119.6 | 100.8 | 89.2 | 90.5 | 98.1 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Foreign exchange earnings (INR Mn) | 885.09 | 1,030.72 | 729.29 | 928.56 |
FX earnings as % of revenue | 76.73 | 67.60 | 50.00 | 61.65 |
FX earnings growth (%) | 0 | 16.45 | -29.25 | 27.32 |
Foreign exchange outgo (INR Mn) | 90.61 | 120.78 | 33.25 | 91.36 |
Revenue by Region and Region Margins & Growth (%) (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Direct export sales (INR Mn) | 729.78 | 958.10 |
Domestic incl. deemed-export sales (INR Mn) | 728.79 | 548.07 |
Direct export growth (%) | 0 | 31.29 |
Domestic / deemed growth (%) | 0 | -24.80 |
Direct exports as % of revenue | 50.03 | 63.61 |
Region Overview
| Region | Markets named | Regulatory character | Direction |
|---|---|---|---|
UK & Europe | UK; EU partners | Regulated (MHRA, EU-GMP) | Core CRAMS market; MHRA audit satisfactorily completed in FY2026 |
Australasia | Australia; New Zealand flagged as potential | Regulated (TGA) | 5 new registrations in FY2026 |
Africa | Nigeria, Kenya, Uganda, Ghana, Ethiopia, Rwanda, Tanzania, Madagascar, DRC/Congo, Mauritius | Semi-regulated / emerging | Fast-growing registration base (Nigeria 13 new in FY2026) |
Asia | Philippines, Sri Lanka, Nepal | Emerging | Philippines 20 new registrations in FY2026, the largest single market for new filings |
CIS | Ukraine, Azerbaijan, Georgia; Russia and Uzbekistan named as targets | Emerging | 4 new registrations in FY2026 |
Latin America | Bolivia, Guatemala, Peru, Nicaragua; Brazil, Mexico and Chile as future targets | Emerging | Groundwork stage |
MENA | UAE, Saudi Arabia, Egypt as potential markets | Not yet active | Future |
North America | Targeted for diabetes and oncology launches | Highly regulated (US FDA) | No filing disclosed |
Share Price and Market Valuation
| Metric | Mar2022 | Mar2023 | Mar2024 | Mar2025 | Mar2026 | Oct2026 |
|---|---|---|---|---|---|---|
Closing price (INR) | 126.65 | 82.00 | 78.35 | 74.80 | 109.34 | 461.35 |
Market cap (INR Mn) | 2,996 | 1,940 | 1,853 | 1,769 | 2,587 | 10,914 |
Valuation Multiples (x) and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | Current |
|---|---|---|---|---|---|---|
P/E (x) | 57.44 | 17.11 | 25.23 | 42.61 | 23.30 | 142.21 |
EV/EBITDA (x) | 25.07 | 12.30 | 15.74 | 16.43 | 17.48 | 96.76 |
EV/Sales (x) | 3.57 | 1.82 | 1.27 | 1.33 | 1.93 | 7.90 |
P/B (x) | 4.84 | 2.64 | 2.29 | 2.09 | 2.69 | 11.35 |
Enterprise value (INR Mn) | 3,042 | 2,104 | 1,941 | 1,945 | 2,908 | 11,268 |
Credit Ratings
| Agency | Instrument | Rating / outlook | Date |
|---|---|---|---|
ICRA | Long-term term loans (INR 258.7 M) | [ICRA]BB+ (Positive) | 23 Jan 2026 |
ICRA | Long-term cash credit (INR 200.0 M) | [ICRA]BB+ (Positive) | 23 Jan 2026 |
ICRA | Long-term unallocated (INR 41.3 M) | [ICRA]BB+ (Positive) | 23 Jan 2026 |
ICRA | Short-term letter of credit (INR 50.0 M, interchangeable) | [ICRA]A4+ | 23 Jan 2026 |
Moody's / S&P / Fitch | — | Not rated | — |
Analyst Conclusions
Management guidance
The only quantified targets are:
-
an EBITDA margin of at least 15% (versus 13.75% in FY2026);
-
6–8 dossier filings a year;
-
capex of INR 75 M in FY2027 (ICRA);
-
"minimum-debt status".
There is no revenue guidance and there are no earnings calls. Q2 FY2027 results are due in the first half of November 2026, after the trading-window closure that began on 1 Oct 2026.
Consensus growth expectations
Not available, because the stock has no institutional coverage.
Bull case
-
Operating leverage on a capex cycle that is now complete. Net PP&E rose from INR 388 M to INR 849 M over FY2022–FY2026. Capsules are only about 30% utilised and tablets about 65%. If capsules reach 60% utilisation, mostly incremental gross margin with capex falling to about INR 75 M, revenue could grow 20–30% and free cash flow could turn decisively positive.
-
Mix shift to regulated and potent products. Exports rose 31% in FY2026, potent capacity has expanded and 51 registrations were won in one year. Sustaining the H1 FY2026 margin profile (15% EBITDA per ICRA) would make the at-least-15% target credible. On a normalised basis — INR 1,800 M revenue at a 15% margin — EBITDA would be about INR 270 M.
-
Credit and governance normalisation. A Positive ICRA outlook, MPS compliance, a cleaner board and audit-trail remediation could bring an investment-grade rating, lower interest cost and broader institutional ownership.
Bear case
-
The FY2026 profit spike looks lumpy, not structural. Quarterly operating margins fell from 12.0% (Q2) to about 8% (Q3–Q4). Q1 FY2027 PAT of INR 0.8 M on revenue down 23% suggests the H1 FY2026 high-margin orders were one-offs. TTM PAT has already fallen to about INR 78 M.
-
Concentration and single-site fragility. With 78% of revenue from five customers and 45% from three commodity molecules, a single customer loss, MHRA observation or machinery failure (as in FY2025) can erase a year's profit. There is no second plant to absorb disruption.
-
Valuation is untethered from fundamentals. At about 142x trailing earnings, about 97x EV/EBITDA and 11x book, the equity values Bafna at about INR 11.3 bn. That is close to 10x Lincoln Pharma on a revenue-adjusted basis, for a business with lower margins, negative cumulative free cash flow and rising debt. Exchange surveillance, thin float and circuit-bound trading mean exit liquidity may vanish on any disappointment.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q2 FY2027 results | Nov 2026 | Whether revenue recovers above INR 350 M per quarter and operating margin above 10% |
| H1 FY2027 balance sheet | Nov 2026 | Refinancing of INR 197 M current maturities; cash; receivable days |
| ICRA surveillance | Around Jan 2027 | Positive outlook converted to upgrade, or reverted to Stable |
| GST / IGST litigation in the Madras HC | Ongoing | Any adverse order on the INR 56.7 M demands |
| Board composition | Near term | Appointment of a third independent director to restore headroom |
| Capsule utilisation and new customers | FY2027 | Any named CRAMS contract or out-licensing deal |
| North America / LATAM / CIS filings | FY2027 | First US-facing filing or dossier submission |
| Promoter actions | Ongoing | Any further SRJR stake sale, preferential issue or corporate restructuring that could explain the re-rating |
| Price-surveillance actions | Ongoing | ASM/GSM framework changes; exchange clarifications |
| Tax normalisation | FY2027–FY2028 | Exhaustion of loss carry-forwards |
Analyst verdict
Bafna Pharmaceuticals is a genuine turnaround story at the operating level. Six years after an NCLT-supervised resolution, it runs a single Chennai solid-oral plant with UK-MHRA, EU-GMP and TGA accreditations — credentials that many larger Indian peers lack. It has rebuilt revenue to INR 1.5 bn, doubled its fixed-asset base, added high-containment potent capacity and, in FY2026, delivered its best post-resolution profit of INR 111 M on a 13.75% EBITDA margin. Its export pivot (+31%), 51 new registrations and a Positive ICRA outlook show real progress.
The evidence does not support a structurally higher-quality business, however. FY2026 profitability was concentrated in the first half: ICRA's 15.1% H1 margin gave way to roughly 8% operating margins in Q3 and Q4. Q1 FY2027 then delivered near-zero profit on a 23% revenue decline. The business remains exposed to five customers (78% of sales), three commodity molecules (45%) and one plant. Free cash flow has been negative cumulatively over five years, and debt has more than tripled. Governance has improved but repeatedly falls short of LODR requirements, and the board now has only two independent directors.
Against this backdrop, the market capitalisation has risen about fourfold since March 2026 to about INR 1,090 crore, with no disclosed corporate event. The company itself told the exchanges it was unaware of any trigger. That implies about 142x trailing earnings and about 97x EV/EBITDA, multiples that price in successful execution of Bafna 2.0 several years ahead.
Verdict: the business deserves cautious interest, but the current valuation does not. On fundamentals the stock screens as substantially overvalued, with a skewed risk–reward and impaired liquidity. A constructive stance would require two or more consecutive quarters of revenue above INR 400 M at an EBITDA margin of 15% or more, positive free cash flow, a named new regulated-market contract and restoration of independent-director headroom. Until then, Bafna is a show-me turnaround trading at a speculative price.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (latest disclosed) |
|---|---|---|---|---|
Bafna Mahaveer Chand | Chief Executive Officer; founder and promoter-group member | Founder since 1981; CEO since 10 Sep 2020 (earlier MD); re-appointed as CEO Sep 2025 | More than 30 years in pharma manufacturing; was the resolution applicant under the 2019–20 NCLT process | FY2024 remuneration was 22.99x the median employee, up 100% year on year (AR FY2023-24) |
Dr. Melagiri Sridhar | Chief Financial Officer | Since 27 May 2017 (MCA data) | Not publicly detailed | FY2024: 4.98x median, +14% |
A. Mohanachandran | Company Secretary & Compliance Officer | Since 29 May 2024 (succeeded Vishnu Vasudeva Kuppa) | Not publicly detailed | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Category | Appointed / tenure | Age | Education / prior roles |
|---|---|---|---|---|
Ms. Ravichandran Chitra (DIN 07749125) | Chairperson, Independent Director | Second term from 12 Nov 2025 | — | B.Com; PGDPMIR (Madras School of Social Work); 30+ years in HR, training and governance |
Mr. Palamadai Krishnan Sundaresan (DIN 06954189) | Independent Director; Chair of Audit Committee and NRC from 23 Jun 2026 | Second term from 19 Sep 2025 | — | CMA and CS; 40+ years in corporate finance, FEMA, M&A and restructuring |
Ms. Shanmugam Hemalatha (DIN 02714329) | Whole-Time Director (commercial, strategy, finance) | Board since 10 Sep 2020; re-appointed for 5 years to 9 Sep 2028 | 51 (born 19 Apr 1975) | B.Com, CS (Inter), ICWA (Inter); 20+ years at the company |
Mr. Vinayak Dinesh Dendukuri (DIN 07601309) | Whole-Time Director (Quality) | 26 Jun 2023 to 24 Jun 2028 | — | BS Biotechnology (RIT); MS (University of Rochester); co-founder of NOVICK Biosciences; ex-Quintiles drug-safety scientist; research roles at Sanofi Pasteur and GSK (USA) |
Mr. Upendar Mekala Reddy (DIN 08898174) | Non-Executive, Non-Independent (promoter nominee; Designated Partner, SRJR Lifesciences LLP) | Since 26 Jun 2023; re-appointed by rotation at 31st AGM | 44 (born 10 Dec 1981) | MBA Finance (IIM Kozhikode); B.Tech CSE (JNTU); FRM; iLabs Group; ex-Edelweiss VP, IL&FS Financial Services, L&T Infrastructure Finance |
Ms. Akila Chintalapati Raju (DIN 07590312) | Non-Executive, Non-Independent | On board by FY2023 | — | LL.M. (NYU); former in-house counsel at Strides Shasun (Australia set-up); litigation practice in Hyderabad |
“—” = not publicly disclosed.
Major Shareholders
| Shareholder | Category | Shares | Stake (%) | As of |
|---|---|---|---|---|
SRJR Lifesciences LLP | Promoter | 17,640,016 | 74.57 | Mar–Jun 2026 |
P. Paras Bafna | Promoter group | 50,000 | 0.21 | Jun 2026 |
Navin Bafna | Promoter group | 42,015 | 0.18 | Jun 2026 |
Mahaveer Chand Bafna | Promoter group | 6,338 | 0.03 | Jun 2026 |
Amri Bai Bafna | Promoter group | 1,989 | 0.01 | Jun 2026 |
Sasikala Bafna | Promoter group | 1,844 | 0.01 | Jun 2026 |
M7 Global Fund PCC – Aerion | FPI | 760,059 | 3.21 | 2026 (Bajaj Finserv data) |
M7 Global Fund PCC – Cell Dewcap Fund | FPI | 737,158 | 3.12 | 2,026 |
Zeal Global Opportunities Fund | FPI | 712,586 | 3.01 | 2,026 |
Alpana Mundra | Individual (public) | not stated | 2.91 | Jul 2025 (MarketsMojo) |
Governance Overview
| Metric | Dec2020 | Dec2021 | Sep2023 | Sep2024 | Mar2025 | Jun2026 |
|---|---|---|---|---|---|---|
Promoter holding (%) | 92.64 | 90.42 | 88.74 | 88.30 | 75.00 | 75.00 |
FII holding (%) | 0 | 0 | 0 | 0 | 8.53 | 9.34 |
Competitive Landscape
Key Competitors
| Competitor | Arena of overlap | Scale / metrics (latest available) | Relative positioning vs. Bafna |
|---|---|---|---|
Lincoln Pharmaceuticals | Emerging-market branded generics exports (Africa, LATAM), domestic | TTM revenue INR 694 crore; PAT INR 96.45 crore; net margin 13.1%; ROE 13.1%; market cap INR 1,183 crore; P/E 12.3 (Value Research, 25 Sep 2026) | About 5x Bafna's revenue at a similar market cap |
Caplin Point Laboratories | LATAM / emerging-market generics; US injectables | TTM revenue INR 2,287 crore; PAT INR 678 crore; net margin 28.1%; ROE 19.7%; P/E 28.6 (Value Research, 9 Oct 2026) | Best-in-class emerging-market model; about 16x Bafna's revenue |
Shilpa Medicare | Oncology / potent formulations; CDMO | TTM revenue INR 1,682 crore; PAT INR 273.5 crore; ROE 11.2%; P/E 66.7 | Integrated API-to-formulation potent player |
Strides Pharma Science | UK/Australia generics; emerging markets | — | Both customer and competitor; vastly larger |
Marksans Pharma | UK and Australia OTC/Rx generics (owns UK MAH businesses) | — | Direct competitor in UK solid orals with owned front-ends |
Kilitch Drugs (India) | Emerging-market (Africa) formulations exporter | Market cap INR 677.6 crore; P/E 22.5; ROE 10.8% (Motilal Oswal, 6 Aug 2026) | Closest micro-cap analogue |
Jenburkt Pharmaceuticals | Branded formulations (India and exports) | Market cap INR 510.6 crore; P/E 14.7; ROE 17.6% | Higher ROE, lower valuation |
Influx Healthtech | Contract manufacturing (nutraceutical/pharma) | Market cap INR 672.5 crore; P/E 32.7; ROE 20.4% | CMO peer |
Amanta Healthcare | Contract manufacturing (parenterals) and exports | Market cap INR 658.3 crore; P/E 44.9; ROE 6.8% | CMO peer |
Medicamen Biotech | Oncology / potent oral formulations for export | — | Overlap in potent oncology |
Peer Comparison FY2026
| Metric | Bafna Pharma | Lincoln Pharma | Caplin Point | Shilpa Medicare |
|---|---|---|---|---|
TTM revenue (INR Cr) | 143 | 694 | 2,287 | 1,682 |
TTM net profit (INR Cr) | 7.79 | 96.45 | 678.07 | 273.51 |
Net margin (%) | 5.24 | 13.09 | 28.10 | 16.19 |
ROE (%) | 8.31 | 13.09 | 19.73 | 11.15 |
P/E (x) | 127 | 12.3 | 28.6 | 66.7 |
P/B (x) | 10.3 | 1.5 | 5.2 | 7.4 |
R&D intensity (%) | 1.73 (FY2026) | — | — | — |
Revenue growth FY2026 (%) | 3.26 | — | — | — |



